Skip to contents
Sebastian G. Schneeweiss, S.M., SCD, MD
Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Phar Epid & Phar Econ
75 Francis Street
Boston, MA 02115


Edit Profile


Education:
Harvard School of Public Health, 2000, SCD
Harvard School of Public Health, 1994, S.M.
Ludwig-Maximilian University Medical School, 1992, MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Glynn RJ, Lunt M, Rothman KJ, Poole C, Schneeweiss S, Stürmer T. Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiol Drug Saf. 2019 Aug 05.

2. Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med. 2019 Jul 30.

3. Schneeweiss S, Brown J, Bate A, Trifirò G, Bartels D. Choosing Among Common Data Models for Real World Data Analyses Fit for Making Decisions about the Effectiveness of Medical Products. Clin Pharmacol Ther. 2019 Jul 22.

4. Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Saf. 2019 Jul 18.

5. Bohn J, Schneeweiss S, Glynn RJ, Toh S, Wyss R, Desai R, Gagne JJ. Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Wash DC). 2019 Jul 15; 7(1):27.

6. Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Saf. 2019 Jul 13.

7. Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture Risk After Initiation of Use of Canagliflozin. Ann Intern Med. 2019 Jul 02; 171(1):80.

8. Patorno E, Schneeweiss S, Gopalakrishnan C, Martin D, Franklin JM. Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. Diabetes Care. 2019 Jun 25.

9. Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sørensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI. CMAJ. 2019 Jun 24; 191(25):E689-E708.

10. Spoendlin J, Paik JM, Tsacogianis T, Kim SC, Schneeweiss S, Desai RJ. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Intern Med. 2019 Jun 01; 179(6):741-749.